What Dodicile Treats: Main Uses and Benefits

Dodicile is a neurotropic B vitamin complex relevant for conditions presenting with systemic or localized discomfort. Its components are relevant for addressing these manifestations in clinical settings that involve acute or unstable symptom patterns, particularly in contexts marked by increased discomfort or tension.

Supportive Care for Nerve Dysfunction Symptoms

Dodicile is applied across domains where additional symptomatic support is needed in addressing the symptoms related to physical discomfort of peripheral neuropathy. This complex helps address symptom clusters like chronic tingling, numbness, and nerve pain (neuralgia), and is relevant for easing symptoms associated with episodic or fluctuating manifestations. It is commonly used to help manage symptoms that interfere with daily functioning.

Management of Underlying B Vitamin Deficiencies

The medication is commonly used in contexts marked by nutritional deficits, specifically B1 and B12 deficiencies. It is relevant in conditions presenting with systemic or localized discomfort, such as anemia (Megaloblastic Anemia) or neuropathy linked to organ-specific functional stress. It is applied across domains where additional symptomatic support is needed. It is relevant for managing symptoms that interfere with daily comfort.

---

Quick Fact: Relief for Neuropathic Discomfort

Use Category	Common Indications Addressed	Primary Symptom Focus
Therapeutic Domain	Deficiency, Peripheral Neuropathy	Tingling, Numbness, Nerve Pain
Clinical Scenarios	Diabetes Support, Malabsorption Issues	Chronic Discomfort, Functional Strain

---

Who can and cannot use Dodicile?

The eligibility for Dodicile is strictly defined by official regulatory criteria for fixed-dose neurotropic B vitamin combinations.

Contraindicated Populations

The medicine is contraindicated in patients with a known history of hypersensitivity to Cyanocobalamin, Thiamine Hydrochloride, or any excipient in the formulation. Use is also absolutely prohibited for patients diagnosed with Leber's disease (hereditary optic nerve atrophy) due to risk of severe optic nerve damage. Certain regulatory documents also list 2nd or 3rd degree arterial hypertension as a contraindication.

Age-Related and Condition-Specific Restrictions

Use is generally authorized for adults and adolescents over 15 years. Treatment is not recommended for children below 14 years. The injectable solution is specifically contraindicated in infants younger than 6 months. Eligibility is conditional in patients with impaired kidney function requiring prolonged parenteral administration, due to the potential for component accumulation. Use is also restricted in cases of suspected megaloblastic anemia prior to definitive diagnosis. For pregnancy and lactation, the official safety status for the combination product is often not established.

The official interaction profile of Dodicile is defined by several documented patterns affecting the active components, Cyanocobalamin and Thiamine.

The most extensive interaction domain involves medicinal products that lead to the reduction of Cyanocobalamin absorption. These include H2-blockers, Proton Pump Inhibitors, and Biguanides (like Metformin), which affect gastric acid necessary for B12 release. Additionally, certain anticonvulsants, Aminoglycosides, Colchicine, and Aminosalicylic acid are noted in regulatory documents as potentially reducing absorption. The use of oral contraceptives is also documented to decrease serum B12 concentration.

A separate domain covers pharmacodynamic interference. Regulatory information states that Chloramphenicol may inhibit the expected hematologic response to Cyanocobalamin. The anti-cancer medicine Fluorouracil is also documented to affect the action of the Thiamine component.

A formal restriction states that the product is contraindicated for use in individuals with Leber's hereditary optic nerve atrophy. Furthermore, a non-medicinal substance interaction is noted with heavy, long-term alcohol intake, which is documented to induce Cyanocobalamin malabsorption. For the parenteral solution, a population-specific note exists regarding the risk of aluminum accumulation in patients with renal impairment.

The mechanism of Dodicile, a fixed-dose combination of Thiamine (B1) and Cyanocobalamin (B12), is a cofactor-based mechanism that directly influences metabolic and structural processes within the nervous system.

Neuro-Energetic Stabilization

The Thiamine component serves as a precursor to Thiamine Diphosphate (ThDP). ThDP is a mandatory cofactor for key mitochondrial enzymes, including the Pyruvate Dehydrogenase Complex, that drive the Tricarboxylic Acid (TCA) Cycle . By optimizing these pathways, the mechanism facilitates necessary ATP production and influences the maintenance of cellular energy status in high-metabolism nerve cells.

Neuro-Structural Maintenance and Integrity

The Cyanocobalamin component is converted to active forms, such as Methylcobalamin, which acts as a cofactor for Methionine Synthase. This enzyme is vital for generating S-adenosylmethionine (SAM), the methyl donor required for synthesizing phospholipids and the protective myelin sheath. This process influences the structural integrity and renewal of components of axons and peripheral nerve tissue. The components act synergistically, with Thiamine providing the energy (ATP) required to fuel the intensive synthesis processes driven by Cyanocobalamin, influencing the overall functional and structural state of the nervous system.

Administration Guidelines for Dodicile

The following parameters outline the methods and procedural requirements for the administration of the veterinary medicinal product Dodicile.

Dodicile is indicated for use in the following Target Species: Cattle, Dog, Cat, Pig, and Horse.

---

Official Administration and Dosing

Procedural Element	Technical Specification
Route of Administration	Intramuscular use or Intravenous use is specified.
Target Species Dosing	Cattle, horses: 5–10 ml. Calves, foals: 2.5–5 ml. Dogs, cats: 0.5–1.5 ml.
Frequency Pattern	May be repeated every 5–7 days, if deemed necessary.

Procedural and Safety Requirements

All administration must follow standard aseptic precautions. A key procedural condition related to food safety is the mandated Withdrawal Period for food-producing species, which must be observed after the final administration of the medicine.

Food Product	Withdrawal Period (Last Dose to Consumption)
Milk (Cattle, Horse)	0 hours
Meat and Offal (Cattle, Dog, Cat, Pig, Horse)	0 days

This 0-hour and 0-day period provides the necessary interval for milk and tissues to be cleared for human consumption immediately following the last administration, maintaining compliance with food safety standards.

Research evidence / Overview of studies for Dodicile

Evidence for Supportive Care in Symptoms of Nerve Discomfort

Research has explored the use of fixed-dose combinations of neurotropic B vitamins, including B1 and B12, in research exploring how symptoms change over time related to peripheral neuropathy. Studies conducted in this area often include Randomized Controlled Trials (RCTs) where the combination was evaluated against a control group, with research exploring outcomes related to physical discomfort. Researchers examined patient-reported outcomes describing perceived discomfort, focusing on measurements of nerve pain (neuralgia), tingling, and numbness over defined time intervals. Research also reports measurements from functional scales, with studies observing responses related to daily functioning or activity level.

Evidence for Management of Underlying B Vitamin Deficiencies

The role of B1 and B12 administration was studied in research examining nutritional status. This evidence is derived from Intervention Studies and Systematic Reviews that focus on patient groups with documented deficiencies, such as those caused by malabsorption issues. Research monitored outcomes related to systemic or functional imbalance, specifically looking at key biomarkers used to describe and track deficiency. Studies monitoring these physiological strain markers over defined time intervals are relevant to the evidence base for B12 administration in documented deficiency.

Long-Term Studies and Follow-up Durations

Research has explored both short-term symptom changes and extended observation periods. The primary follow-up durations for comprehensive evaluation of functional outcomes were typically 12 weeks. This timeframe was relevant in trials assessing short-term or episodic symptom patterns. However, long-term effects are not fully established. There is limited information available for long-term outcomes, such as sustained symptom patterns beyond one year, meaning that certainty remains low regarding sustained effects.

What is Still Uncertain About Dodicile Research

The existing research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain. A key uncertainty is the specific composition of the FDC. Most high-quality evidence from systematic reviews focuses on a three-vitamin complex (B1, B6, and B12). Therefore, research describes that data for the specific B1/B12 FDC (Dodicile) is limited. Comparative evidence against B1 or B12 monotherapy for nerve discomfort is also lacking in the broader evidence landscape.

Key Studies & References

1. Management of peripheral neuropathy symptoms with a fixed dose combination of high-dose vitamin B1, B6 and B12: A 12-week prospective non-interventional study in Indonesia
2. Diagnosis, Treatment and Long-Term Management of Vitamin B12 Deficiency in Adults: A Delphi Expert Consensus

Common questions about Dodicile (FAQ)

---

Q: What are the reported long-term effects of taking Dodicile?

Studies and official information indicate that long-term outcomes for this specific fixed-dose combination, particularly sustained effects beyond one year, are not fully established. Research provides limited information in this area, meaning certainty about the long-term profile remains low.

---

Q: Can Dodicile affect sleep or cause insomnia?

While regulatory safety documents do not explicitly list insomnia as a reported side effect, the medicine is associated with Nervous System Disorders. These are classified as seldom or uncommon effects and may include dizziness and headache.

---

Q: Can people with kidney problems use Dodicile?

According to official product information, eligibility for Dodicile is conditional for patients who have impaired kidney function. Caution is specifically advised when using the injectable solution due to the potential risk of aluminum accumulation in the body.

---

Q: Does Dodicile require special monitoring or blood tests for certain conditions?

Official labeling includes cautions related to certain blood conditions. Regulatory documents note that caution is advised regarding use because there is a risk of unmasking a condition called polycythemia vera. Furthermore, it is restricted for use in cases of suspected megaloblastic anemia until a definitive diagnosis is confirmed.

---

Q: How is Dodicile different from similar medications for the same condition?

Research has noted that high-quality evidence from systematic reviews often focuses on a three-vitamin complex (B1, B6, and B12), indicating that data specifically for the B1/B12 FDC (Dodicile) is comparatively limited in the broader research landscape.

---

Q: What were the key findings from the main studies on Dodicile?

Research explored the use of B1/B12 FDC in relation to symptoms of nerve discomfort. Researchers examined patient-reported outcomes describing perceived discomfort, focusing on measurements of nerve pain (neuralgia), tingling, and numbness. Studies also observed responses related to overall daily functioning and activity level.

---

Q: Why does Dodicile have a warning about driving or operating machinery?

The official product information lists Nervous System Disorders, such as dizziness and headache, as seldom or uncommon side effects. These kinds of effects could potentially impair the user's ability to drive or operate complex machinery.

How to Store and Dispose of Dodicile?

Dodicile's official storage and disposal requirements ensure product stability and environmental safety.

---

Storage Conditions

Requirement	Specific Condition
Temperature	Store below 25°C and do not store in the refrigerator.
Protection	Must be stored protected from heat and light sources.
Child Safety	Keep the medicine out of the sight and reach of children.

The unopened product has a shelf life of 2 years. After the container is first opened, the solution for injection must be used within 28 days.

---

Disposal Instructions

Unused or expired Dodicile and associated waste must be disposed of in accordance with national requirements. It is mandatory that the product is not disposed of via wastewater to protect the environment.